Caminati, Marco
De Corso, Eugenio
Ottaviano, Giancarlo
Pipolo, Carlotta
Schiappoli, Michele
Seccia, Veronica
Spinelli, Francesca Romana
Savarino, Edoardo Vincenzo
Gisondi, Paolo
Senna, Gianenrico
Article History
Accepted: 29 November 2023
First Online: 12 December 2023
Compliance with Ethical Standards
:
: Eugenio de Corso: speaker activity and advisory boards participation for: Sanofi, Novartis, Regeneron, GSK, Astrazeneca, and Firma. Edoardo Vincenzo Savarino has served as speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, Mayoly Biohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, and Unifarco; has served as consultant for Abbvie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr. Falk, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestlè, and Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco, and Zeta Farmaceutici. Giancarlo Ottaviano has received fees for consultation, speaker activity, and served on advisory boards for Sanofi, GSK, and Novartis. The other authors declare non-financial interests that are directly or indirectly related to the work submitted for publication.
: This article does not contain any studies with human or animal subjects performed by any of the authors.